Enhanced Exon-skipping Induced by U7 SnRNA Carrying a Splicing Silencer Sequence: Promising Tool for DMD Therapy

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2009 May 21

PMID 19455105

Citations 34

Authors

Aurelie Goyenvalle

Arran Babbs

Gert-Jan B van Ommen

Luis Garcia

Kay E Davies

Affiliations

Soon will be listed here.

Abstract

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. In most cases, the open-reading frame is disrupted which results in the absence of functional protein. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD and has recently been shown to correct the reading frame and restore dystrophin expression in vitro and in vivo. Specific exon skipping can be achieved using synthetic oligonucleotides or viral vectors encoding modified small nuclear RNAs (snRNAs), by masking important splicing sites. In this study, we demonstrate that enhanced exon skipping can be induced by a U7 snRNA carrying binding sites for the heterogeneous ribonucleoprotein A1 (hnRNPA1). In DMD patient cells, bifunctional U7 snRNAs harboring silencer motifs induce complete skipping of exon 51, and thus restore dystrophin expression to near wild-type levels. Furthermore, we show the efficacy of these constructs in vivo in transgenic mice carrying the entire human DMD locus after intramuscular injection of adeno-associated virus (AAV) vectors encoding the bifunctional U7 snRNA. These new constructs are very promising for the optimization of therapeutic exon skipping for DMD, but also offer powerful and versatile tools to modulate pre-mRNA splicing in a wide range of applications.

Citing Articles

From computational models of the splicing code to regulatory mechanisms and therapeutic implications.

Capitanchik C, Wilkins O, Wagner N, Gagneur J, Ule J Nat Rev Genet. 2024; 26(3):171-190.

PMID: 39358547 DOI: 10.1038/s41576-024-00774-2.

RNA-Based Therapeutic Technology.

Mashima R, Takada S, Miyamoto Y Int J Mol Sci. 2023; 24(20).

PMID: 37894911 PMC: 10607345. DOI: 10.3390/ijms242015230.

Development of Engineered-U1 snRNA Therapies: Current Status.

Goncalves M, Santos J, Coutinho M, Matos L, Alves S Int J Mol Sci. 2023; 24(19).

PMID: 37834063 PMC: 10572768. DOI: 10.3390/ijms241914617.

Functional investigation of SCN1A deep-intronic variants activating poison exons inclusion.

Sparber P, Bychkov I, Pyankov D, Skoblov M Hum Genet. 2023; 142(8):1043-1053.

PMID: 37186029 DOI: 10.1007/s00439-023-02564-y.

Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders.

Morelli K, Smargon A, Yeo G RNA. 2023; 29(4):489-497.

PMID: 36693761 PMC: 10019361. DOI: 10.1261/rna.079519.122.

References

t Hoen P, de Meijer E, Boer J, Vossen R, Turk R, Maatman R . Generation and characterization of transgenic mice with the full-length human DMD gene. J Biol Chem. 2007; 283(9):5899-907. DOI: 10.1074/jbc.M709410200. View

Benchaouir R, Meregalli M, Farini A, DAntona G, Belicchi M, Goyenvalle A . Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell. 2008; 1(6):646-57. DOI: 10.1016/j.stem.2007.09.016. View

Villemaire J, Dion I, Elela S, Chabot B . Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides. J Biol Chem. 2003; 278(50):50031-9. DOI: 10.1074/jbc.M308897200. View

Aartsma-Rus A, Bremmer-Bout M, Janson A, den Dunnen J, van Ommen G, van Deutekom J . Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 2002; 12 Suppl 1:S71-7. DOI: 10.1016/s0960-8966(02)00086-x. View

Koenig M, Beggs A, Moyer M, Scherpf S, Heindrich K, Bettecken T . The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989; 45(4):498-506. PMC: 1683519. View

Monaco A, Bertelson C, Moser H, Kunkel L . An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2(1):90-5. DOI: 10.1016/0888-7543(88)90113-9. View

Arechavala-Gomeza V, Graham I, Popplewell L, Adams A, Aartsma-Rus A, Kinali M . Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 2007; 18(9):798-810. DOI: 10.1089/hum.2006.061. View

VandenDriessche T, Naldini L, Collen D, Chuah M . Oncoretroviral and lentiviral vector-mediated gene therapy. Methods Enzymol. 2002; 346:573-89. DOI: 10.1016/s0076-6879(02)46078-8. View

Mann C, Honeyman K, Cheng A, Ly T, LLOYD F, Fletcher S . Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A. 2000; 98(1):42-7. PMC: 14541. DOI: 10.1073/pnas.98.1.42. View

10.

Blankinship M, Gregorevic P, Chamberlain J . Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther. 2005; 13(2):241-9. DOI: 10.1016/j.ymthe.2005.11.001. View

11.

Aartsma-Rus A, Janson A, Heemskerk J, De Winter C, van Ommen G, Van Deutekom J . Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides. Ann N Y Acad Sci. 2006; 1082:74-6. DOI: 10.1196/annals.1348.058. View

12.

Dunckley M, Manoharan M, Villiet P, Eperon I, Dickson G . Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 1998; 7(7):1083-90. DOI: 10.1093/hmg/7.7.1083. View

13.

Wilton S, Fall A, Harding P, McClorey G, Coleman C, Fletcher S . Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther. 2007; 15(7):1288-96. DOI: 10.1038/sj.mt.6300095. View

14.

Snyder R, Spratt S, Lagarde C, Bohl D, Kaspar B, Sloan B . Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 1998; 8(16):1891-900. DOI: 10.1089/hum.1997.8.16-1891. View

15.

van Deutekom J, Bremmer-Bout M, Janson A, Ginjaar I, Baas F, den Dunnen J . Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001; 10(15):1547-54. DOI: 10.1093/hmg/10.15.1547. View

16.

Zhu C, Mouly V, Cooper R, Mamchaoui K, Bigot A, Shay J . Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell. 2007; 6(4):515-23. DOI: 10.1111/j.1474-9726.2007.00306.x. View

17.

Bremmer-Bout M, Aartsma-Rus A, de Meijer E, Kaman W, Janson A, Vossen R . Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther. 2004; 10(2):232-40. DOI: 10.1016/j.ymthe.2004.05.031. View

18.

Moser H . Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet. 1984; 66(1):17-40. DOI: 10.1007/BF00275183. View

19.

Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan J, Garcia L . Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004; 306(5702):1796-9. DOI: 10.1126/science.1104297. View

20.

Brun C, Suter D, Pauli C, Dunant P, Lochmuller H, Burgunder J . U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci. 2003; 60(3):557-66. PMC: 11138867. DOI: 10.1007/s000180300047. View